Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types
|
|
- Winifred Bradford
- 5 years ago
- Views:
Transcription
1 Rotarix : Global Efficacy against Severe RV GE due to G1 and non-g1 (G2, G3, G4, G9) RV Types 8 th International Rotavirus Symposium Istanbul, 3 rd June 2008 Dr. Norman Begg, Vice President, Clinical Development GlaxoSmithKline Biologicals, Rixensart, Belgium
2 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
3 Percent Efficacy Rational for Vaccination with Human RV Strain Natural RV infection attenuates severity of subsequent infections, regardless of serotype One Previous RV infection moderate to severe diarrhea mild diarrhea asymptomatic infection 62 Two Previous RV infections 1 Velazquez et al, N Eng J Med ; 2 Bernstein DI, et al. JID. 1991; 164(2); ; 3 Velazquez et al, J Infect Dis
4 Human RV Vaccine - Rotarix Lyopholized vaccine + liquid diluent (CaCO 3 ) 1 ml per dose Each dose: 10 6 CCID 50 of live, attenuated HRV strain G1 P(8) Orally administered 2 doses 1 st dose beginning at 6 weeks of age 2 nd dose at 4 weeks after first dose; completed by 24 weeks of age GlaxoSmithKline Biologicals, Rotarix TM Summary of Product Characteristics (Dec. 2007)
5 Pivotal phase III studies in Latin America and Europe Ruiz-Palacios et al. for the Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: Vesikari et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:
6 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
7 No increased risk of Intussusception Vaccine group Placebo group Safety cohort N=31,673 Safety cohort N=31,552 Cases of IS 0 31 days days Relative Risk = 0.85 (0.30 ; 2.42)* 9 16 Relative Risk = 0.56 (0.25 ; 1.24)* No increased risk for IS compared to placebo Ruiz-Palacios G. et al. N. Engl. J. Med. 2006; 354: ; Macias M. et al., abstract, ICAAC, 2005, Washington, USA (poster) *95% CI
8 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
9 Latin America: Type-specific Efficacy for Severe Rotavirus GE From 2 weeks post-dose 2 until 24 months of age (ATP cohort) Vaccine efficacy (%) * Not statistically significant G1P[8] G2P[4] G3P[8] G4P[8] G9P[8] Low Number of G2P[4] due to low circulation of strain type Linhares, A.C., et al. Lancet 2008 Apr 5;371(9619): % [65;92] 79% [25;96] 39%* [<0;84] 62% [4;87] 87% [73;94]
10 Europe: Type-specific Efficacy for Severe Rotavirus GE From 2 weeks post-dose 2 until end of the 2 nd RV season (ATP cohort) Vaccine efficacy (%) % [90;99] 86% [24;99] 94% [53;100] 95% [68;100] 85% [72;93] G1P[8] G2P[4] G3P[8] G4P[8] G9P[8] Vesikari T, et al. Lancet 2007 Nov 24;370(9601):
11 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
12 Latin America: Efficacy over peak incidence (2 years) From 2 weeks post-dose 2 until 12 months of age From 2 weeks post-dose 2 until 24 months of age Vaccine efficacy (%) % [71;93] 81% [71;87] Severe RV GE Vesikari 85% [70;94] RV GE hosp. 83% [73;90] Severe RV GE Vesikari RV GE Hospitalization 40% [29;53] 39% [29;48] All causes Severe GE All-cause Severe GE Linhares AC, et al. Lancet 2008 Apr 5;371(9619):1181-9
13 Europe: Efficacy lasting 2 seasons From 2 weeks post-dose 2 until end of the 1st RV season (ATP cohort) From 2 weeks post-dose 2 until end of the 2nd RV season (ATP cohort) Vaccine efficacy (%) % [80;92] 79% [73;84] 96% [90;99] 90% [85;94] 100% 96% [82;100] [84;100] 92% [84;96] 84% [77;89] Any RV GE Severe RV GE RV GE Hosp Medicallyattended RV GE Vesikari T, et al. Lancet 2007 Nov 24;370(9601): % [46;89] 72% [53;83] All-cause GE Hosp
14 Europe: Efficacy after one dose From Dose 1 up to before Dose 2 (Total Vaccinated Cohort) Vaccine efficiacy (%) % [9;100] Any RV GE 100% [-23;100] Severe RV GE Vesikari T, et al. Lancet 2007 Nov 24;370(9601): ; GlaxoSmithKline Biologicals, Rotarix Summary of Product Characteristics (Dec 2007) According to Rotarix Summary of Product characteristics 2 doses are indicated.
15 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
16 Co-administration with other vaccines DTPw, DTPa, HBV, Hib, IPV, OPV, Men C, PCV-7 High Rotarix immune responses maintained No impairment of immune responses to any co-administered vaccine antigens Vesikari et al. PIDJ 2004,23: Salinas B et al. PIDJ, /9: Phua K et al. JID, 2005;192(suppl 1): S6-S16 Ruiz-Palacios G. et al. N. Engl. J. Med. 2006; 354: Tejedor JC et al. ESPID, Basel, Switzerland May 3 5, 2006, Abstract 456, Schuster VT et al. ESPID, Basel, Switzerland May 3 5, 2006, Abstract 461
17 Latin America (Rota 024): Co-administration of Rotarix with Oral Polio Vaccine Infants of 6-12 weeks % [54;93] 88% [64;97] Co-administration: OPV + 2 doses RIX4414 or Placebo (n=4376) (n=2192) Vaccine efficacy (%) Efficacy follow-up: 7.4m 10 0 Severe RV GE RV GE Hospitalization No impact on the efficacy of Rotarix In line with the high efficacy against severe RVGE of 85% demonstrated in the Latin American study with staggered OPV co-administration Tregnaghi, M. et al., Abstract, 13th ICID Kuala Lumpur, Malaysia- June 19-22,
18 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
19 Ease of inclusion in immunisation schedules Oral presentation 2 doses Flexible schedule starting from 6 weeks of age No interference with currently co-administered vaccines Rotarix can be flexibly integrated into a variety childhood immunisation schedules: 6,10 weeks; 6,14 weeks; 10,14 weeks; 2, 3 months; 2, 4 months; 3, 4 months or 3, 5 months of age Vesikari et al. PIDJ 2004,23: Salinas B et al. PIDJ, /9: Phua K et al. JID, 2005;192(suppl 1): S6-S16 Ruiz-Palacios G. et al. N. Engl. J. Med. 2006; 354: Tejedor JC et al. ESPID, Basel, Switzerland May 3 5, 2006, Abstract 456, Schuster VT et al. ESPID, Basel, Switzerland May 3 5, 2006, Abstract 461
20 Challenges for the development of a global Rotavirus vaccine No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age and peak incidence period No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
21 Variance in serotype distribution G4P[8] 3.4% G9P[8] 17.2% G3P[8] 12.1% GXP[6] 1.7% Unknown 3.4% Latin America G1P[8] 51.7% 1 st Year Europe G9P[8] 33.9% G1P[8]+G4P[8] 0.8% G1P[8] 41.5% G2P[4] 12.1% G4P[8] 12.7% G3P[8] 5.1% G2P[4] 5.9% G9P[8] 54.4% G3P[6] 1.0% G1P[8] 24.3% G4P[8] 15.6% G2P[4] 1.0% G3P[8] 5.8% 2 nd Year Mixed 2.3% G12P[8] 1.2% G9P[8] 39.2% G4P[8] 4.7% Linhares AC, et al. Lancet 2008 Apr 5;371(9619): ; Vesikari T, et al. Lancet 2007 Nov 24;370(9601): Unknown 4.1% G3P[8] 4.1% G1P[8] 31.6% G2P[4] 12.9%
22 Efficacy in all Regions Rota-023 (11 countries) Severe RV GE 1 year 85% (71-93) 2 years 81% (71-87) Hospitalization for RV GE 1 year 85% (70-94) 2 years 83% (73-90) Linhares AC, et al. Lancet 2008 Apr 5;371(9619): Rota-036 (6 countries) Severe RV GE1 season 96% (90-99) 2 seasons 90% (85-94) Hospitalization for RV GE 1 season 100% (82-100) 2 seasons 96.0% (84-100) Any RV GE 1 season 87% (80-92) 2 seasons 79% (73-84) Vesikari T, et al. Lancet 2007 Nov 24;370(9601): Rota-024 OPV co-ad (6 countries) Severe RV GE 1st year 82% (54-93) Hospitalization for RV GE 1st year 88% (64-97) Lopez, P. et al., Abstract, 13th ICID Kuala Lumpur, Malaysia- June 19-22, Rota-028/029/030 (3 countries) Severe RV GE 1 year 100% (72-100) 2 years 96% (86-100) Hospitalization for RV GE 1 year 100% (67-100) 2 years 94% (81-99) Phua, K.B. et al., Abstract, 13th ICID Kuala Lumpur, Malaysia- June 19-22, Rota-037 Interim analysis to be presented at 8 th International RV symposium Madhi, S., Oral presentation, 8th international Rotavirus Symposium, Istambul, Turkey, June 3-4,
23 Summary: Rotarix No increased risk of IS compared to placebo Broad protection against known and emerging strains Efficacy from an early age, lasting 2 years No interference with co-administered antigens Ease of inclusion in immunisation schedules Efficacy in developing and developed countries
A Human Rotavirus Vaccine
7th International Rotavirus Symposium Lisbon, Portugal, 12-13 June 2006 A Human Rotavirus Vaccine Dr. Béatrice De Vos GlaxoSmithKline Biologicals Rixensart, Belgium Rotarix is a trade mark of the GlaxoSmithKline
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationDr. Bernd Benninghoff GSK Vaccines, GML Global Medical Affairs Director
ROTARIX the human rotavirus vaccine: -is applied in a 2-dose schedulecompletes the course at the earliest possible age, prevents morbidity and mortality from RV GE regardless of the circulating strains
More informationBangladesh: How to move from data to implementation. K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b
Bangladesh: How to move from data to implementation K. Zaman, MBBS, PhD Senior Scientist and Epidemiologist icddr,b Rotavirus in Bangladesh Estimated 2.4 million cases of rotavirus diarrhoea annually in
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose (1 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID 50 PHARMACEUTICAL
More informationRotarix TM. Rotavirus vaccine. 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID50 PHARMACEUTICAL FORM Oral suspension.
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain* of the G1P[8] type: not less than 10 6.0 CCID 50 *Produced
More informationGSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationValue of post-licensure data to assess public health value Example of rotavirus vaccines
Value of post-licensure data to assess public health value Example of rotavirus vaccines TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines
More informationVaccines against Rotavirus & Norovirus. Umesh D. Parashar CDC, Atlanta, GA
TM Vaccines against Rotavirus & Norovirus Umesh D. Parashar CDC, Atlanta, GA 1 Rotavirus is the Leading Cause Of Severe Diarrhea in Children
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationDESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS
DESCRIPTION OF STUDIES AND RISK OF BIAS ASSESSMENT FOR RCTS ROTAVIRUS VACCINES SCHEDULES: A SYSTEMATIC REVIEW OF SAFETY AND EFFICACY FROM RANDOMIZED CONTROLLED TRIALS AND OBSERVATIONAL STUDIES OF CHILDHOOD
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationFor the use only of registered medical practitioners or a hospital or a laboratory ROTARIX. Rotavirus Vaccine (Live Attenuated, Oral) IP
For the use only of registered medical practitioners or a hospital or a laboratory ROTARIX Rotavirus Vaccine (Live Attenuated, Oral) IP 1. NAME OF THE MEDICINAL PRODUCT Rotavirus Vaccine (Live Attenuated,
More informationUpdates on Rotasiil development
Updates on Rotasiil development 13 th International Rotavirus Symposium Minsk, Belarus 30 August 2018 Dr Sajjad Desai MD Serum Institute of India Pvt Limited, Pune Rotasiil Bovine-human reassortant strains
More informationRotavirus vaccines: Issues not fully addressed in efficacy trials
Rotavirus vaccines: Issues not fully addressed in efficacy trials TM Umesh D. Parashar Lead, Viral Gastroenteritis Team CDC, Atlanta, USA uparashar@cdc.gov 1 Two New Rotavirus Vaccines Licensed in 2006
More informationThe Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond
The Pentavalent Rotavirus Vaccine, RotaTeq : From Development to Licensure and Beyond Max Ciarlet, PhD Vaccines Clinical Research Department Merck Research Laboratories North Wales, Pennsylvania, United
More informationPrevention of Rotavirus Infections. Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti
Prevention of Rotavirus Infections Dr. ANCA DRAGANESCU INBI Matei Bals Bucuresti Worldwide, Rotavirus Accounted for ~215,000 Childhood Deaths Annually 1 (2000-2013) In children less than 5 years of age:
More informationGSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus vaccine Study No.: (EPI-ROTA ) Title:
GSK Medicine: Rotarix (HRV): GlaxoSmithKline Biologicals live attenuated human rotavirus Study No.: 111426 (EPI-ROTA-111426) Title: Case-control study to evaluate the effectiveness of GlaxoSmithKline (GSK)
More informationGlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert
GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design
GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination
More informationPRODUCT INFORMATION Rotavirus vaccine live attenuated oral
PRODUCT INFORMATION Rotavirus vaccine live attenuated oral NAME OF THE MEDICINE ROTARIX Human rotavirus (live attenuated oral vaccine) oral liquid DESCRIPTION ROTARIX is a liquid suspension of the live
More informationCan we improve the performance of live oral rotavirus vaccines?
Can we improve the performance of live oral rotavirus vaccines? Duncan Steele 9 th International Rotavirus Symposium 2 & 3 August 2010, Johannesburg, South Africa Vaccine efficacy against severe rotavirus
More informationRotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April
Rotavirus serotype surveillance: Results and experiences in Tanzania Adolfine Hokororo KPA Vaccinology Symposium- 29 th April 2016 1 outline 1. Introduction-burden of RVGE 2. goals of RVGE sentinel surveillance
More informationEfficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study
Eur J Pediatr (2010) 169:1379 1386 DOI 10.1007/s00431-010-1242-3 ORIGINAL PAPER Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish Extension Study
More informationAppendix I: Patient-relevant outcomes, literature search, inclusion and exclusion criteria, flow charts
Appendices I-V Koch J, Wiese-Posselt M, Remschmidt C, Wichmann O, Bertelsmann H, Garbe E, Hengel H, Meerpohl JJ, Mas Marques A, Oppermann H, Hummers-Pradier E, von Kries R, Mertens T. Background paper
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationROTAVIRUS VACCINES. Virology
ROTAVIRUS VACCINES Virology Rotavirus is a triple-layers viral particle belonging to the Reoviridae family. It contains 11 segments of double-stranded RNA, of which 6 are structural and 5 are non-structural
More informationROTARIX (Rotavirus Vaccine, Live, Oral) Oral Suspension Initial U.S. Approval: 2008
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ROTARIX safely and effectively. See full prescribing information for ROTARIX. ROTARIX (Rotavirus
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET. PRODUCT NAME ROTARIX Human rotavirus (live attenuated oral vaccine) oral liquid 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ROTARIX is a liquid suspension of the live attenuated
More informationAssessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University
Assessing public health impact through vaccine probe analyses Robert F. Breiman Emory Global Health Institute Emory University State of understanding the relative role of pathogens in major disease syndromes
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationGSK Vaccine Development
GSK Vaccine Development Innovation and new technology to provide a solution Sub-regional Symposium on Pneumococcal in the Caribbean Dominican Republic, Oct 1-2 nd, 2008 Alejandro Lepetic, MD Medical Affairs
More informationNew and Underused Vaccines, Rotavirus
New and Underused Vaccines, Rotavirus George Armah Noguchi Memorial Institute for Medical research University of Ghana 10th Annual African Vaccinology Course (VACFA) Cape town, South Africa 10 th to 14
More informationHexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines
Viral Hepatitis Prevention Board Hanoi, 25 26 July 2018 Hexavalent Vaccines: Hepatitis B antibody response and co-administration with other vaccines Prof. Timo Vesikari Vaccine Research Center University
More information8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM
PROCEEDINGS FROM THE 8 th INTERNATIONAL ROTAVIRUS SYMPOSIUM June 3 4, 2008 Istanbul, Acknowledgements The Symposium Organizing Committee wishes to thank the following organizations for support of the 8th
More informationROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS
ROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS Summary Rotavirus is the most common cause of severe gastroenteritis in infants and young children, accounting
More informationBurden of Rotavirus in India - Is Rotavirus Vaccine an Answer to It?
Special Article Burden of Rotavirus in India - Is Rotavirus Vaccine an Answer to It? *Davendra K. Taneja 1, Akash Malik 2 1 Professor, 2 P.G.T, Department of Community Medicine, Maulana Azad Medical College,
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ROTARIX safely and effectively. See full prescribing information for ROTARIX. ROTARIX (Rotavirus
More informationI mun u i n s i atio i n o n u p u d p a d te
Immunisation update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of Cape Town Immunisation schedules,
More informationBurden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination
Carlo GIAQUINTO Pediatrics Department University of Padova, Italy Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Preliminary results 7th International Rotavirus
More informationGlobal Impact of Enteric Disease Deaths in young children
1 Global Impact of Enteric Disease Deaths in young children 2 Average of 2.2 million deaths per year worldwide Typhoid 600 000 Cholera 120 000 ETEC 380 000 Rotavirus 450 000 Shigella 670 000 WHO, 2000
More informationRotavirus Vaccines. Gagandeep Kang Christian Medical College Vellore
Rotavirus Vaccines Gagandeep Kang Christian Medical College Vellore Rotavirus disease burden Rotavirus vaccines and candidates Performance of vaccines in developed and developing countries Longitudinal
More informationHaemophilus influenzae type B and Hib Vaccine Chapter 9
Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae Aerobic gram-negative bacteria Polysaccharide capsule Six different serotypes (a-f) of polysaccharide capsule 95% of invasive
More informationEffect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico
original article Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico Vesta Richardson, M.D., Joselito Hernandez-Pichardo, M.D., Manjari Quintanar-Solares, M.D., Marcelino Esparza-Aguilar,
More informationLessons from Rotavirus Vaccine Implementation in the U.S.
Lessons from Rotavirus Vaccine Implementation in the U.S. Jeff Duchin, MD Chief, Communicable Disease Epidemiology & Immunization Section Public Health - Seattle & King County Professor in Medicine, Division
More informationRotavirus Infections and Vaccinations in
Rotavirus Infections and Vaccinations in Children under Five in Lebanon Hassan Zaraket, RPh, PhD Assistant Professor Department of Microbiology and Immunology Member, Center for Infectious Diseases Research
More informationSUPPLEMENT ARTICLE. of Africa and Asia. The highest rates of rotavirus-associated mortality occur in sub-saharan Africa, where
SUPPLEMENT ARTICLE Comparison of 2 Different Regimens for Reactogenicity, Safety, and Immunogenicity of the Live Attenuated Oral Rotavirus Vaccine RIX4414 Coadministered with Oral Polio Vaccine in South
More informationUS Rotavirus Vaccination Program
US Rotavirus Vaccination Program 1 Rotavirus Vaccines in US Feb 2006 Feb 2006 April 2008 June 2008 RotaTeq licensed by FDA RotaTeq recommended by ACIP Rotarix licensed by FDA ACIP to consider Rotarix 2
More informationCase study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan
15 th ADVAC Case study Rota in Sudan Case study: Evaluation of Rotavirus vaccine impact and safety following introduction into the national immunizations programme of Sudan Background Rotavirus is one
More informationImmunisation Subcommittee of PTAC Meeting held 6 March (minutes for web publishing)
Immunisation Subcommittee of PTAC Meeting held 6 March 2013 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and
More informationGSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
More informationAssessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University
Assessing Vaccine Safety Post Licensure Neal A. Halsey Johns Hopkins University Inactivated Respiratory Syncytial Virus Vaccine: 1960 s Formalin inactivated Administered to infants Minimal reactions Induced
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationShabir A. Madhi. Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality.
Shabir A. Madhi Progress and Challenges of Immunization Contributing Toward Attaining the MDG Goal to Reduce under-5 Childhood Mortality. National Institute for Communicable Diseases & University of Witwatersrand,
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME NEW ZEALAND DATA SHEET HIBERIX Haemophilus influenzae type b (Hib) powder and diluent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose
More informationRotavirus. Factsheet for parents. Immunisation for babies up to a year old
Rotavirus Factsheet for parents This factsheet describes the rotavirus infection and the vaccine that protects against it. It also provides the background to the development and introduction of the vaccination
More informationSustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization
Clinical Infectious Diseases SUPPLEMENT ARTICLE Sustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization Edgar Sánchez-Uribe,
More informationAlternative Rotavirus Vaccine Candidates: Why should we bother?
Alternative Rotavirus Vaccine Candidates: Why should we bother? Duncan Steele Initiative for Vaccine Research, WHO 7 th International Rotavirus Symposium 12-13 June 2006, Lisboa, Portugal Rotavirus Vaccines
More informationCopyright 2008 by Lippincott Williams & Wilkins.Unauthorized reproduction of this article is prohibited.
Journal of Pediatric Gastroenterology and Nutrition 46:S38 S48 # 2008 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,
More informationPrevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine
POLICY STATEMENT Prevention of Rotavirus Disease: Updated Guidelines for Use of Rotavirus Vaccine Committee on Infectious Diseases Organizational Principles to Guide and Define the Child Health Care System
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEffectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases
TECHNICAL DOCUMENT Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Effectiveness
More informationRotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation
SUPPLEMENT ARTICLE Rotavirus Vaccines for Infants in Developing Countries in Africa and Asia: Considerations from a World Health Organization Sponsored Consultation A. Duncan Steele, 1,2 Manish Patel,
More informationPopulation effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies
Hungerford et al BMC Infectious Diseases (2017) 17:569 DOI 101186/s12879-017-2613-4 RESEARCH ARTICLE Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and
More informationConclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas
Conclusions and Recommendations of the Experts Meeting on Rotavirus Genotypes in the Region of the Americas Eyal Leshem December 9, 2013 National Center for Immunization & Respiratory Diseases Division
More informationViral Agents of Paediatric Gastroenteritis
Viral Agents of Paediatric Gastroenteritis Dr Carl Kirkwood -------------------- Enteric Virus Research Group Murdoch Childrens Research Institute Royal Children s Hospital Victoria. WHO Collaborating
More informationTo demonstrate that DTPa-HBV-IPV/Hib-MenC-TT co-administered with 10Pn, is non-inferior to DTPa-HBV-IPV/Hib coadministered
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationA rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months.
A rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months. Rotavirus is a very common and potentially serious
More informationDr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine
Dr Michelle Groome MBBCh (Wits) DCH(SA) MScMed (Epi & Biostats) Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases; Medical Research Council: Respiratory and
More informationACTIVE SURVEILLANCE FOR INTUSSUSCEPTION IN A PHASE III EFFICACY TRIAL OF AN ORAL MONOVALENT ROTAVIRUS VACCINE IN INDIA.
ACTIVE SURVEILLANCE FOR INTUSSUSCEPTION IN A PHASE III EFFICACY TRIAL OF AN ORAL MONOVALENT ROTAVIRUS VACCINE IN INDIA. Sangeeth Rajkumar Christian Medical College, Vellore ORV 116E Phase III trial plan
More informationVaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV
Supplemental Digital Content 1. Methodology Inclusion and exclusion criteria Eligible participants were infants between and including 6 10 weeks of age at the time of the first vaccination, who were free
More informationSolution for Oral Administration RotaTeq (rotavirus vaccine, live, oral, pentavalent, MSD)
Solution for Oral Administration RotaTeq (rotavirus vaccine, live, oral, pentavalent, MSD) I. THERAPEUTIC CLASS RotaTeq is a live, oral liquid pentavalent vaccine which protects against rotavirus gastroenteritis.
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationThe reassortants are propagated in Vero cells using standard tissue culture techniques in the absence of antifungal agents.
NEW ZEALAND DATA SHEET Name of Medicine RotaTeq rotavirus vaccine, live, oral, pentavalent Single dose 2 ml unit dosing tube Presentation RotaTeq is available as a single, pre-filled 2 ml unit dose in
More informationUNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013
UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 Presentation overview Scope of UNICEF procurement Overview of UNICEF procurement Vaccine market updates UNICEF procures
More informationLiterature Rotavirus vaccines
Literature Rotavirus vaccines Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol. 2012 Aug;2(4):419-25. doi: 10.1016/j.coviro.2012.05.003. Epub 2012
More informationSyrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation
Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,
More informationINFORMATION SHEET OBSERVED RATE OF VACCINE REACTIONS ROTAVIRUS VACCINE
Global Vaccine safety Essential Medicines & Health Products 20, Avenue Appia, Ch- 1211 Geneva 27 INFORMATION SHEET OBSERVED RATE OF VACCINE REACTIONS ROTAVIRUS VACCINE June 2018 Types of vaccines Rotaviruses
More informationABSTRACT. n engl j med 362;4 nejm.org january 28,
The new england journal of medicine established in 1812 january 28, 2010 vol. 362 no. 4 Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants Shabir A. Madhi, M.D., Nigel A. Cunliffe,
More informationRequirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.
Requirements for new trials to examine offtarget effects of vaccination Workshop on: Off-target (heterologous/non-specific) effects of vaccination Les Pensieres Jun 8-10, 2015 PEM Fine London School of
More informationArticles. Funding GlaxoSmithKline.
Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled
More information9/11/2018. Rotavirus. Rotavirus. Rotavirus. First identified as a cause of diarrhea in 1973
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Rotavirus September 2018 Photographs and images included in this presentation are licensed solely for
More informationWould a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children?
Would a combined PCV10+PCV13 immunization schedule be a cost-effective option for Canadian children? Philippe De Wals Department of Social and Preventive Medicine, Laval University Quebec University Hospital
More informationReceived 16 September 2014; revised 14 October 2014; accepted 10 November 2014
Open Journal of Pediatrics, 2014, 4, 291-299 Published Online December 2014 in SciRes. http://www.scirp.org/journal/ojped http://dx.doi.org/10.4236/ojped.2014.44040 Impact of Rotavirus Vaccination in Severe
More informationDealing with Post-market Issues: PCV Case Study
Dealing with Post-market Issues: PCV Case Study CASE STUDY: Adventitious agent in raw material ISSUE: Presence of porcine circovirus (PCV-1) DNA detected in marketed rotavirus vaccine by an independent
More informationCost-Effectiveness of Rotavirus Vaccination in Peru
Cost-Effectiveness of Rotavirus Vaccination in Peru Andrew D Clark 1, Damian G Walker 1 2, N. Rocio Mosqueira 3, Mary E Penny 3, Claudio F Lanata 3 4, Colin FB Sanderson 1 1 London School of Hygiene and
More informationAssessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation
Assessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation Karen Farizo, M.D. Office of Vaccines Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationVaccines for Children
Vaccines for Children 0-9 old Our goal is to offer your family the best care possible, which includes making sure your child is up to date on all vaccines. DTaP (Diptheria, Tetanus, Pertussis) Vaccine
More informationcorrespondence Rotavirus Vaccines
correspondence Rotavirus Vaccines To the Editor: The rotavirus vaccines in the clinical trials reported on by Ruiz-Palacios and colleagues and Vesikari and colleagues (Jan. 5 issue) 1,2 may reduce mortality
More informationHow to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries?
How to measure impact of rotavirus vaccination: Opportunities for synergies across Nordic countries? Elmira Flem Department of Vaccines Norwegian Institute of Public Health Nordic Vaccine Meeting April
More informationSYNFLORIX TM. adsorbed on aluminium phosphate 0.5 milligram Al conjugated to protein D (derived from NTHi) carrier protein 9-16 micrograms 3
1. NAME OF THE MEDICINAL PRODUCT SYNFLORIX TM Synflorix TM suspension for injection Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationNo of studies/starting rating 8 studies-all RCTs (32,854 participants) 2 4. Inconsistency none 0. Indirectness none 0. Imprecision none 0
Grading of scientific evidence Tables 1 4: Does RV1and RV5 induce protection against rotavirus morbidity and mortality in young children both in low and highmortality settings? Table 1: EFFECTIVENESS OF
More informationCyprus Experience. Dr. Elena Papamichael Ministry of Health
Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey
More informationCopyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
More information